Immunotherapy is currently one of the most groundbreaking areas of cancer treatment. This advanced treatment uses your immune cells to attack cancer cells in your body. One kind of immunotherapy is being used now to treat certain blood cancers. That treatment is a type of engineered cell therapy called chimeric antigen receptor (CAR) T-cell therapy.
The physicians and researchers at UCLA Health are at the forefront of engineered cell innovation. In 2018, UCLA Health became one of the first hospitals in the nation to offer CAR T-cell therapy to people whose cancer hasn’t responded to other treatments. In 2020, UCLA became one of the first to offer CAR T-cell therapy to treat relapsed or refractory mantel cell lymphoma.
For more information, please call one of the following numbers and let our staff know that you are calling about CAR T-cell therapy:
CAR T-cell therapy activates a person’s immune system to fight off cancer. Immunotherapy is still relatively new, but it shows promise for adults and children for whom other treatments have stopped working.
T cells are the central components of the immune system. In CAR T-cell therapy, T cells are first removed from a sample of blood. Then, in the laboratory, specialists modify the cells so they will recognize and attack cancer cells.
The modified cells then are returned to the patient’s body. If the treatment is successful, the newly modified T cells will help a person’s immune system kill off cancer cells, sending the disease into remission.
This kind of immunotherapy is being studied for a variety of blood cancers. Currently, three types of CAR T-cell therapy have moved beyond clinical trials. They are being used to treat:
Find out more about how the Bone Marrow Transplant team at UCLA Health is using CAR T-cell treatment.
In experimental studies, CAR T-cell therapy was an effective treatment for blood cancer and bone marrow disorders such as leukemia and lymphoma. The team at UCLA Health helped to pioneer this immunotherapy research by participating in CAR T-cell therapy clinical trials before FDA approval.
Because of this experience, our team has unparalleled knowledge in CAR T-cell therapy. Highlights of our program include:
For more information about CAR T-cell therapy at UCLA Health, please call 888-662-8252.